Clinical trial
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and…
NCT02990338 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT02990338 |
|---|---|
| Title | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients |
| Official title | A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma |
| Acronym | ICARIA-MM |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Plasma Cell Myeloma |
| Intervention type | Drug |
| Interventions | Isatuximab, Pomalidomide, Dexamethasone |
| Enrollment | 307 |
| Start date | Dec 22, 2016 |
| Primary completion | Nov 22, 2018 |
| Completion | Nov 1, 2023 |
| First posted | Dec 13, 2016 |
| Last update posted | Jan 17, 2025 |
| Countries | Australia, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Japan, New Zealand and 12 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: